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Introduction
Granulomatosis with polyangiitis (GPA) is an 
uncommon immunologically mediated systemic 
disease of unknown aetiology that is pathologi-
cally characterised by an inflammatory reaction 
pattern (necrosis, granulomatous inflammation and 
vasculitis) that occurs in the upper and lower res-
piratory tracts and kidneys. GPA is an autoimmune 
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multisystemic small-vessel vasculitis1 that is 
included in the group of anti-neutrophil cytoplas-
mic antibody (ANCA)-associated small-vessel 
vasculitides.
The disease was initially described by Klinger in 
1931 as a variant of polyarteritis nodosa and was 
described for the first time as a separated syndrome 
by Friedrich Wegener in two articles appearing in 
1936 and 1939.2,3
In 1954, Godman and Churg introduced the term 
‘Wegener’s granulomatosis’ and further delineated 
the clinical and pathological features,4 establishing 
the criteria to diagnose the disease: (1) granuloma 
in the upper airways; (2) necrotising vasculitis; and 
(3) glomerulonephritis.
Until recently the disease was known as 
Wegener’s granulomatosis, but it has now been 
renamed ‘Granulomatosis with polyangiitis (GPA)’.5
Although the aetiology of GPA remains largely 
unknown, it is believed to be autoimmune in origin, 
triggered by environmental events on a poorly char-
acterised background of genetic susceptibility.6,7
GPA is a relatively rare condition.8 In Europe 
the prevalence of GPA is five cases per 100,000 
population, with greater incidence in Northern 
Europe. GPA can occur in all racial groups but pre-
dominantly affects Caucasians. Both sexes are 
affected equally. GPA affects a wide age range (age 
range, 8–99 years), with a mean age at diagnosis of 
40 years.9 A review of major literature in the last 10 
years was performed.
Clinical manifestations
GPA is characterised by necrotising granulomatous 
lesions of the respiratory tract, vasculitis and glo-
merulonephritis. Classically, the acronym ELK is 
used to describe the clinical involvement of the ear, 
nose and throat (ENT); lungs; and kidneys (Table 1).
In 1953, Fienberg introduced the term of ‘lim-
ited Wegener’s granulomatosis’,10 a concept that 
was subsequently expanded by Carrington and 
Liebow11 and supported by Cassan et al.12 Limited 
GPA is a restricted form of the disease in which 
clinical findings are initially present only 
locoregionally.13
The current classification of GPA describes lim-
ited GPA as a disease involving only one or two of 
the ELK areas.14 Progression to the systemic form 
of GPA is unpredictable when the disease is left 
untreated.15
Classic otorhinolaryngologic symptoms may be 
the initial clinical manifestation of GPA because 
the upper respiratory tract is involved in 70–100% 
of cases.16 The nasal cavity and the paranasal 
sinuses are the most common sites of involvement 
in the head and neck area (85–100%), whereas oto-
logical disease is found in approximately 35% 
(range, 19–61%) of cases.17 Isolated ear involve-
ment preceding the respiratory and renal manifes-
tations is uncommonly reported.18
Otological involvement may occasionally be the 
first and only sign of GPA;19,20 mastoiditis may be 
the first manifestation of GPA.21 Fauci et al.22 
reported that 25% of patients with GPA presented 
with serous otitis media and that 6% of patients 
presented with hearing loss as the initial sign of the 
disease. Kempf23 reported that approximately half 
of patients with GPA developed otological mani-
festations in the early stage of the disease.
Early diagnosis is essential to prevent long-
term complications. Otological involvement can 
be seen in up to 40% of patients who require early 
appropriate treatment to prevent permanent sen-
sorineural hearing loss or permanent facial nerve 
paralysis. Primary otological presentation occurs 
in 20–25% of patients, and diagnosis can be dif-
ficult when the disease is limited to this locore-
gional phase.24
Otological involvement is divided into the fol-
lowing basic types: (1) serous otitis media, the 
most frequent manifestation,25,26 which results 
from Eustachian tube obstruction and nasopharyn-
geal involvement;19 (2) chronic otitis media, which 
is caused by primary involvement of the middle ear 
and mastoid cavity; (3) sensorineural hearing loss, 
the aetiology of which is unknown but is consid-
ered to involve either: (i) vasculitis of the cochlear 
vessels and deposition of the immune complexes 
in the cochlea; (ii) pressure on the acoustic nerve 
by granulomatous lesions;26,27 or (iii) toxic effects 
of inflammatory by-products arising from the mid-
dle ear through the round window, which adversely 
affect the vasa nervorum and the cochlear ves-
sels;8,28,29 (4) vertigo, thought to be due to either: 
(i) immune complex deposition in the vestibular 
portion or (ii) manifestation of central nervous sys-
tem involvement caused by a polyneuritis; and 
(5) facial nerve palsy, which is seen in 8–10% of 
cases and is usually associated with otitis media.30 
In the majority of cases, facial paralysis improves 
with cytotoxic therapy.
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The typical otologic symptoms in GPA of com-
mon observation by ENT specialist is ANCA-
induced otitis media. The clinical findings of this 
middle otitis are: (1) otitis media following sudden 
progressive hearing loss; (2) intractable otitis 
media not effected by antibiotics and tympanic 
tube insertion; (3) mostly PR3- and or MPO-ANCA 
positive; (4) occasionally clinical complications 
such as facial palsy or hypertrophic pachymeningi-
tis; (5) tympanic membrane showing a dull appear-
ance and vessel dilatation of tympanic membrane, 
granulationor normal appearance only with senso-
rineural hearing loss; (6) effectiveness of corticos-
teroid and immunosuppressive therapy using 
cyclophosphamide or methotrexate.
Conductive hearing loss, sensorineural hearing 
loss or mixed hearing loss can be observed at differ-
ent clinical phases. Conductive hearing loss is caused 
by granulation and effusion in the middle ear, obstruc-
tion of the Eustachian tube, effusion in the middle ear 
caused by vasculitis in the middle ear mucosa.
Sensorineural or mixed hearing loss is caused by 
inflammation in the inner ear, often it is a reversi-
ble hearing loss and it had not progressed to com-
plete deafness.
Nahohiro and Yukiko show, in their study, that 
the reversible nature of the hearing loss indicates 
that the hair cells remain intact. It is known that the 
inner ear maintains a specific ionic balance with 
ions pumping mechanism which ensures a high 
level of K+ ions in the endolymph and creates a 
140–180 mV driving force by stria vascularis for 
positively charged K+ ions to flow through the ste-
reocilia. Hair cells are morphologically coupled to 
fibrocytes and supporting cells by gap junctions 
and K+ ions recirculate from the endolymph to the 
stria vascularis through hair cells and supporting 
cells. The progressive reduction of capillaries 
microcirculation at spiral ligament and Stria vascu-
laris, bring to reduction of Endocochlear Potential 
(EP) (in this phase sensorineural hearing loss is 
established). If the damage persists and is not 
treated pharmacologically this could lead to: struc-
tural dysfunction of stria vascularis, ischemia in 
the inner ear and permanent hair cell damage with 
inner ear damage and definitive hearing loss.
The temporal bone histopathology of cases of 
complete deafness caused by GPA showed that 
tympanic granulation and inflammatory substances 
also invade the inner ear through the round window, 
Table 1. Clinical manifestations in GPA.
Organ Clinical manifestation
Generic General malaise, myalgia, arthralgia, anorexia, weight loss and pyrexia
Skin Leucocytoclastic vasculitis, digital infarcts, purpura, cutaneous ulcers and gangrene
Oral cavity Oral ulcers, oral granulomatous lesions, gingival hyperplasia with strawberry-like aspect, swallow
Eye Episcleritis, scleritis, conjunctivitis, keratitis, uveitis, retinal vasculitis, retinal arterial or venous 
thrombosis, retinal exudates, retinal haemorrhages, blurred vision, blindness, proptosis and 
orbital granulomatous masses, epiphora
Nose and paranasal sinus Persistent-recurrent nasal discharges, blood-stained nasal discharge, epistaxis, crusting, mucosal 
ulceration, nasal bridge collapse, nasal granulomatous lesions, parasinus and sinus inflammation, 
regional tenderness
Ear Sensorineural hearing loss and conductive hearing loss
Upper airway Subglottic or tracheal stenosis
Lower airway Cough, breathlessness, stridor, wheeze, small air way obstruction, pulmonary nodules, cavitating 
lung lesions, pleuritis, pleural effusions, pulmonary infiltrates, pulmonary haemorrhage, alveolar 
capillaritis and respiratory failure
Cardiovascular Small vessel vasculitis, occlusive vascular disease, pericarditis, pericardial effusions, 
cardiomyopathy, valvular heart disease, ischaemic heart disease, heart failure
Gastrointestinal Acute abdomen secondary to peritonitis or bowel ischaemia which may be secondary to 
mesenteric vasculitis
Kidney Diffuse pauci-immune crescentic necrotising glomerulonephritis, haematuria, proteinuria, cellular 
casts on urine cytology, renal impairment manifested as acute kidney injury, chronic kidney 
disease or end-stage renal failure
Central and peripheral 
nervous system
Headache, meningitis, seizures, cerebrovascular accidents, spinal cord lesions, cranial nerve 
palsies, sensory or motor peripheral neuropathy, mononeuritis multiplex, sensorineural hearing 
loss, cerebral mass lesions
Musculoskeletal Inflammatory arthritis, erosive or deforming, arhtralgia, myalgia, arthralgia
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the stria vascularis was slightly atrophic and spiral 
ganglion cells were well preserved.31
Biopsy specimens from the head and neck region 
are often small, and it is usually difficult to make a 
definite histologic diagnosis,13,24,32 particularly 
when the biopsy is taken from the middle ear.28,33 
Kempf23 reported that the expected typical histo-
logical picture of GPA was not found in middle ear 
biopsies. Devaney et al.34 reported that only one of 
three mastoid biopsy specimens and none of four 
middle ear specimens showed evidence of GPA. In 
the head and neck region, biopsies from the parana-
sal sinuses showed higher positive rates for GPA. 
Therefore, it is recommended that biopsy speci-
mens be taken from the paranasal sinus or nose.27,35
It has been reported that cytoplasmic (c)-ANCA 
is highly specific for active GPA and that c-ANCA 
titres are directly related to GPA disease activity.36 
At Hokkaido University Graduate School of 
Medicine, treatment for GPA is started when the 
c-ANCA titre is positive and clinical features of 
GPA are present, even if a histological diagnosis 
cannot be made.
Delays in diagnosis and initiation of therapy nega-
tively affect the prognosis for hearing loss. Therefore, 
it is important to start treatment before irreversible 
change occurs in the middle and inner ears.
The most common anatomical site for manifes-
tation of lesions in GPA is the upper airway. GPA 
can also affect the eyes, skin, joints and nervous 
system.37 Renal involvement is characterised by 
abnormal renal function with red cell casts in uri-
nalysis, and glomerulonephritis on renal biopsy.38
The most common features of nasal disease 
activity were crusting, blood-stained rhinorrhoea 
and nasal obstruction. Septal perforation was the 
most common feature of damage (24%). These 
findings agree with case studies reported in the 
literature. Acute pain, fever and mucopurulent 
discharge were reported in 10% of the patients 
and the area most affected was the maxillary 
sinus. The most common organism identified was 
Staphylococcus aureus which has previously been 
associated with GPA activity and relapse.39
The prevalence of subglottic stenosis was 23%, 
while in the reported series it was in the range of 
6–23%.30,40,41 Patients with subglottic stenosis 
were younger than those with a normal subglottis 
and 60% were women. As in other case studies, 
stridor and reduced exercise tolerance were often 
the presenting symptoms.42
Diagnosis
There are no diagnostic criteria for GPA. 
Diagnosis is based on a combination of clinical 
manifestations positive ANCA serology and his-
tological evidence of necrotising vasculitis, 
necrotising glomerulonephritis or granulomatous 
inflammation from a relevant organ biopsy, such 
as skin, lung or kidney.
It should be emphasised that positive ANCA 
serology is not essential for the diagnosis of GPA if 
clinical and histological findings point to a diagno-
sis of GPA should be taken to exclude vasculitis 
mimics or other types of sistemi vasculitis.43
c-ANCA, first reported in 1985 by Wan der 
Woude et al.,36 are highly specific for GPA, espe-
cially in the active phase. Thus, the presence of 
c-ANCA in GPA is a great aid to diagnosis. 
Difficulty in diagnosis often delays the initiation of 
treatment, and the disease occasionally progresses 
to the irreversible phase. The typical ANCA pat-
tern associated with GPA is c-ANCA recognising 
the autoantigen proteinase 3 (PR3), which is a pro-
tease found in the granules of neutrophils. Fewer 
than 20% of patients with GPA have a perinuclear 
pattern recognising the autoantigen myeloperoxi-
dase (MPO).
It was found that ANCA are highly specific for 
this disease, and as a result, there was great opti-
mism about their potential for diagnosis. ANCA 
have two applications: (1) as a diagnostic test; and 
(2) as a marker of disease activity. Contrary to 
opinion, this serological marker has many limita-
tions. Its sensitivity depends on: (1) the stage of the 
disease; and (2) the activity of the disease. Pooled 
ANCA sensitivity for active disease is 91% as 
compared to 63% for inactive disease.44 Pooled 
ANCA sensitivity for active locoregional disease is 
60% as compared to 93% for active generalised 
disease.45 Limited manifestations of GPA have a 
high rate of ANCA false negatives (30%).
ANCA false positives have been reported for 
GPA and the false positive value is determined by 
the prevalence of GPA. Therefore, if the preva-
lence of GPA is low, a positive c-ANCA is very 
likely to be a false positive result.
According to the current literature, screening for 
ANCA begins with indirect immunofluorescence 
assay on fixed human neutrophils, after which is 
followed by methods determining the antigen spe-
cificities of the autoantibodies as proteinase 3 
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(PR3) or myeloperoxidase (MPO). In order to 
avoid false negative results a broad spectrum of 
anti-PR3 detection methods has been developed to 
increase their sensitivity as ELISA test. ELISA 
using a mixture of human native (hn) PR3 com-
bined with the human recombinant (hr) protein 
yield a very high sensitivity, but their specificity 
may vary.46 Qualitative assays of ANCA immuno-
fluorescence identify cytoplasmic c-ANCA, peri-
nuclear p-ANCA and atypical ANCA, while 
enzyme immunosorbent assays with ELISA test 
give quantitative measure of PR3-ANCA and 
MPO-ANCA titres. The use of IF combined with 
ELISA gives a 96% sensitivity and 98.5% specific-
ity for ANCA-associated vasculitides.
In 2011 the American College of Rheumatology 
proposed classification criteria for GPA (Table 2). 
The presence of two or more of these four criteria 
yields a sensitivity of 88%. The presence of two or 
more of these four criteria yields a specificity of 
92%.42
Histologically, it is challenging to diagnose 
GPA from nasal biopsies, and it is rare to see a 
‘full house’ of necrotising granulomata with giant 
cells and neutrophil-predominant vasculitis.45 
The majority of head and neck biopsy specimens 
have non-specific findings. The classical triad of 
vasculitis, necrosis and granulomatous inflamma-
tion can be observed in up to 16% of cases of 
GPA. Vasculitis and granulomas are observed 
together in up to 21% of cases, and in 23% of 
head and neck biopsy specimens one can observe 
vasculitic and necrotic features.34 The technical 
difficulty of obtaining an appropriate biopsy 
specimen from the ear may be a large factor in 
explaining these findings. The majority of pulmo-
nary biopsies show the classical triad of disease 
features.
There are no diagnostic criteria for GPA and 
diagnosis is based on a combination of the clini-
cal manifestations of systemic disease which sug-
gest a diagnosis of vasculitis; positive c-ANCA 
serology and histological evidence of necrotising 
vasculitis, necrotising glomerulonephritis or 
granulomatous inflammation from a relevant 
organ biopsy, such as the skin, lung or kidney. 
Oral lesions are uncommon during clinical anam-
nesis but when this lesions were observed is con-
sidered a distinctive diagnostic criteria for GPA 
and their recognition is most important for timely 
diagnosis.47 Because an otologic disorder may be 
part of the initial clinical presentation of GPA all 
unilateral or bilateral chronic middle otitis not 
satisfying to the local or general antibiotics ther-
apy, or in patients in whom discrepancies 
between otoscopic findings and severe mixed 
hypoacusis are noted, an autoimmune disease can 
be suspected.48,49
The prompt diagnosis of GPA is important for 
prognostic reasons, because immunosuppression 
regimes can induce quickly clinical remission and 
in the long term reduce disease morbidity and mor-
tality. It should be stated that positive ANCA serol-
ogy is not essential for a diagnosis of GPA if the 
clinical and histological evidence can support a 
diagnosis of GPA. Similarly, caution should be 
taken in interpreting positive ANCA serology when 
there are no clinical signs, symptoms or histologi-
cal evidence suggestive of ANCA-associated 
vasculitides.
There are no special diagnostic tests for GPA. 
The otorhinolaringologist is often one of the first 
physicians for patients with GPA. The recognition 
of signs and symptoms of GPA affecting the upper 
respiratory tract is crucial for an effective diagnos-
tic evaluation that allows the timely initiation of 
appropriate therapy.
Detection of ANCA and histological examina-
tion of biopsies are not always sufficient for the 
diagnosis of GPA, which also requires correct 
examination and recording of clinical signs and 
symptoms and exclusion of other causes of the 
clinical presentation. We aimed to identify, charac-
terise and evaluate ENT signs and symptoms in 
GPA patients so that the condition could be identi-
fied at an earlier stage.50
Table 2. The American College of Rheumatology criteria for GPA diagnosis.
Classification criteria  
Nasal or oral inflammation Painful or painless oral ulcers or purulent or bloody nasal discharge
Abnormal chest radiograph Pulmonary nodules, fixed pulmonary infiltrates or pulmonary cavities
Abnormal urinary sediment Microscopic haematuria with or without red cell casts
Granulomatous inflammation Biopsy of an artery or perivascular area shows granulomatous inflammation
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Differential diagnosis
Rheumatoid vasculitis (RV) is a major differential 
diagnosis. RV usually occurs in seropositive rheu-
matoid arthritis (RA) patients with longstanding 
disease. GPA lesions show necrotising granuloma-
tous vasculitis of small vessels, while the RV 
lesions mostly shows leukocytoclastic vasculitis 
(LCV).51 Other differential diagnoses include pyo-
derma gangrenosum, lymphoma, tuberculosis, sar-
coidosis and deep fungal infection.
Otological symptoms must be differentiated 
from sudden sensorineural hearing loss46 and 
Meniere’s syndrome.53 In most cases, gradual hear-
ing loss due to effusion and granulation in the mid-
dle ear is treated as an intractable otitis media. With 
sudden progressive hearing loss, an autoimmune 
disease should be suspected and require extensive 
serological testing.
Prognosis
Left untreated, GPA is a fatal condition, as renal 
failure secondary to renal involvement reduces the 
prognosis for recovery. Therapy for GPA has 
increased survival, resulting in remission in more 
than 90% of patients, particularly in patients who 
have not yet developed major renal damage.14 If 
untreated, the disease usually runs a rapidly fatal 
course, and 82% of patients die within 1 year. Thus, 
accurate and early diagnosis of GPA is of para-
mount importance to improve the prognosis.
The 10-year survival rate is estimated to be 40% 
when the kidneys are involved and 60–70% when 
there is no kidney involvement.54 Therefore, it is 
important to recognise the disease early, as the lim-
ited form of the disease is amenable to effective 
therapy, and effective therapy leads to longer 
patient survival.
Therapy
In 1983, Fauci22 reported the efficacy of treatment 
using a combination of glucocorticoids and cyclo-
phosphamide, and this treatment has become the 
standard for GPA.
Additionally, Gross55 suggested that in young 
patients, cyclophosphamide should be switched to 
azathioprine in the maintenance phase.
Because it was reported that glucocorticoid 
treatment alone cannot achieve complete remission 
of an otological manifestation in patients with 
GPA,35 we recommend the combined use of immu-
nosuppressive drugs when there is middle and 
inner ear involvement.
The majority of GPA patients with serous otitis 
media resulting from Eustachian tube dysfunction 
could be helped by tympanostomy tube place-
ment. Chronic otitis media and sensorineural 
hearing loss in GPA occur from primary involve-
ment of the ear, and both of these symptoms fail 
to respond to conventional treatment such as anti-
biotics. However, early treatment with glucocorti-
coids and cyclophosphamide can resolve these 
symptoms.45 Different authors emphasise that 
surgical intervention in cases of middle ear 
involvement should be minimal and performed 
only for diagnostic purposes, particularly during 
the acute stage.25
Progressive sensorineural hearing loss was evi-
dent in most cases and is one of the major otologi-
cal symptoms. This symptom can be partially 
recovered by treatment with corticosteroid alone 
such as Prednisolone (0.8–1 mg/kg/day) is tapered 
slowly (20% reduced every month) and then main-
tained (5–10 mg/day) while monitoring the ANCA 
titre. However, corticosteroids alone could not 
achieve complete remission in many cases and 
progressed to definitive hearing. In this cases, 
therapy can be enhanced with immunosuppression 
drugs as cyclophosphamide or methotrexate 
although these drugs were questioned for possible 
clinical complications.31
When middle otitis ANCA associated was sus-
pected but the ANCA titre was negative, histology 
of the mastoid granulation taken by mastoidectomy 
or nasal mucosa was recommended, although the 
biopsy from the middle ear specimen showed a 
lower positive rate.
Conclusions
GPA is an idiopathic necrotising systemic vasculi-
tis involving both the upper and lower respiratory 
tracts and the kidneys. The pathogenesis of GPA is 
still unknown, although an autoimmune response 
appears to be involved in the development of the 
disease. In our opinion, for the diagnosis and thera-
peutic treatment of GPA, a multidisciplinary 
approach involving otorhinolaryngologists, oral 
and maxillofacial surgeons, oral physicians, rheu-
matologists, renal and respiratory physicians, and 
ophthalmologists is needed.
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GPA must be considered when patients do not 
improve as expected despite being given adequate 
treatment, when they have unspecific systemic 
symptoms suggesting systemic disease (fever, 
myalgia, arthralgia) or when other organs are 
involved (eyes, kidneys, lungs and others). 
Prolonged evolution times of over 20 days to 
observe the regression of ear inflammation suggests 
a specific aetiology to support disease activity.
Therefore, ENT physicians have a determining 
role in recognising the early onset of the disease 
and starting proper therapy. Occasionally, ear 
conditions are the first and only symptoms to 
appear. We reviewed cases of GPA that presented 
with otological manifestations. The most frequent 
finding was chronic otitis media. Occasionally, 
otological manifestations presented as the first 
sign of the disease, which made diagnosis more 
difficult. Therefore, GPA should be included in 
the differential diagnosis in cases of atypical 
inflammation of the ear. Biopsy specimens are 
often small, and histologic diagnosis from the 
middle ear is usually difficult. c-ANCA is not 
helpful in making a diagnosis in these localised 
cases. Early diagnosis and appropriate treatment 
is important to prevent the progression of this dis-
ease to an irreversible phase.
In conclusion, the early diagnosis and specific 
treatment of GPA is important but difficult to 
achieve because of the multiplicity of presenting 
symptoms and unclear histological features. 
Otological symptoms may be the first clinical fea-
ture of GPA. Therefore, a high level of suspicion 
toward GPA is needed from the otolaryngologist, 
especially when confronted with ineffective pro-
longed antibiotic treatment for otitis media.
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